Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Impax Laboratories, LLC | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 30, 2012
|
Impax Laboratories, Inc.
|
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
001-34263
|
65-0403311
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
30831 Huntwood Avenue, Hayward, CA
|
94544
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code:
|
(510) 240-6000
|
|
Not Applicable
|
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| o |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| o |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| o |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| o |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
On October 30, 2012, Impax Laboratories, Inc. issued a press release announcing its results for the quarter ended September 30, 2012. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
|
(d)
|
Exhibits.
|
The following exhibit is furnished herewith.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued October 30, 2012.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 30, 2012 |
IMPAX LABORATORIES, INC.
|
||
|
By:
|
/s/ Larry Hsu, Ph.D. | ||
| Name: Larry Hsu, Ph.D. | |||
| Title: President and Chief Executive Officer | |||
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press release issued October 30, 2012.
|